Nanostring-Based Multigene Assay to Predict Recurrence for Gastric Cancer Patients after Surgery

Page view(s)
20
Checked on Jan 20, 2024
Nanostring-Based Multigene Assay to Predict Recurrence for Gastric Cancer Patients after Surgery
Title:
Nanostring-Based Multigene Assay to Predict Recurrence for Gastric Cancer Patients after Surgery
Journal Title:
PLoS ONE
Keywords:
Publication Date:
05 March 2014
Citation:
Lee J, Sohn I, Do I-G, Kim K-M, Park SH, et al. (2014) Nanostring-Based Multigene Assay to Predict Recurrence for Gastric Cancer Patients after Surgery. PLoS ONE 9(3): e90133. doi:10.1371/journal.pone.0090133
Abstract:
Despite the benefits from adjuvant chemotherapy or chemoradiotherapy, approximately one-third of stage II gastric cancer (GC) patients developed recurrences. The aim of this study was to develop and validate a prognostic algorithm for gastric cancer (GCPS) that can robustly identify high-risk group for recurrence among stage II patients. A multi-step gene expression profiling study was conducted. First, a microarray gene expression profiling of archived paraffin-embedded tumor blocks was used to identify candidate prognostic genes (N = 432). Second, a focused gene expression assay including prognostic genes was used to develop a robust clinical assay (GCPS) in stage II patients from the same cohort (N = 186). Third, a predefined cut off for the GCPS was validated using an independent stage II cohort (N = 216). The GCPS was validated in another set with stage II GC who underwent surgery without adjuvant treatment (N = 300). GCPS was developed by summing the product of Cox regression coefficients and normalized expression levels of 8 genes (LAMP5, CDC25B, CDK1, CLIP4, LTB4R2, MATN3, NOX4, TFDP1). A prospectively defined cut-point for GCPS classified 22.7% of validation cohort treated with chemoradiotherapy (N = 216) as high-risk group with 5-year recurrence rate of 58.6% compared to 85.4% in the low risk group (hazard ratio for recurrence = 3.16, p = 0.00004). GCPS also identified high-risk group among stage II patients treated with surgery only (hazard ratio = 1.77, p = 0.0053).
License type:
http://creativecommons.org/licenses/by/4.0/
Funding Info:
Description:
ISSN:
1932-6203
Files uploaded: